<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02271711</url>
  </required_header>
  <id_info>
    <org_study_id>2013-0765</org_study_id>
    <secondary_id>NCI-2014-02677</secondary_id>
    <nct_id>NCT02271711</nct_id>
  </id_info>
  <brief_title>Study of Intraventricular Infusions of Autologous ex Vivo-expanded NK Cells in Children With Recurrent/Refractory Malignant Posterior Fossa Tumors of the Central Nervous System. NOAH's (New Opportunity, Advancing Hope) Protocol</brief_title>
  <official_title>Phase I Study of Intraventricular Infusions of Autologous ex Vivo-expanded NK Cells in Children With Recurrent/Refractory Malignant Posterior Fossa Tumors of the Central Nervous System. NOAH's (New Opportunity, Advancing Hope) Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if infusions of a particular type of
      patients' own white blood cells called natural killer (NK) cells can reliably and safely be
      given to patients with brain tumors after the cells have been through a procedure to expand
      (increase) their numbers.

      Researchers also want to learn if NK cells infused through the ommaya reservoir can help to
      control the disease in patients with advanced brain tumors. The ommaya reservoir is a
      catheter system through which NK cells will be infused directly into areas of the brain
      called the fourth ventricle or the lateral.

      This is the first study of intraventricular NK cell infusions (infusions into the ventricle
      of the brain) in humans.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Groups:

      If you are found to be eligible to take part in this study, you will be assigned to a dose
      level of NK cells based on when you join this study. Up to 4 dose levels of NK cells will be
      tested. Up to 6 participants will be enrolled at each dose level. The first group of
      participants will receive the lowest dose level. Each new group will receive a higher dose
      than the group before it, if no intolerable side effects were seen. This will continue until
      the highest tolerable dose of NK cells is found.

      NK Cell Collection, Expansion, and Infusion:

      Blood (up to 10 tablespoons) will be drawn through your central venous catheter if you have
      one, or through a needle stick.

      Your NK cells will then be processed in The Cell Therapy Laboratory GMP facility at MD
      Anderson to make increased numbers of NK cells. Leftover blood from this process and/or extra
      NK cells beyond what is needed for the study will be used to study the appearance and
      function of your NK cells.

      Your NK cells will be destroyed if the cells show some form of abnormal cell growth during
      the process and are unsafe for infusion, if you are found to not be eligible to receive the
      infusions, or if you leave the study early.

      If you do not already have an Ommaya catheter that has been placed in the lateral or fourth
      ventricle of your brain, you will have one placed before receiving the NK cells. You will
      sign a separate surgical consent form that will describe the procedure in more detail.

      You will receive the NK cells 1 time a week (at least 3 days apart) for the first 3 weeks in
      each 4-week cycle. These infusions will be given to you over about 3 minutes through the
      ommaya reservoir catheter.

      On the days of the NK cell infusions, you will take the following drugs to lower the risk of
      side effects:

      -You will take Tylenol (acetaminophen) by mouth before the infusion. If the doctor thinks it
      is needed, you will take it again 4-6 hours later.

      Study Visits:

      The screening tests may be repeated if your NK cell infusion is delayed more than 30 days.

      If more than 4 weeks have passed since you had an MRI at screening, it will need to be
      repeated before receiving the NK cells in Cycle 1.

      Before receiving the first NK cell infusion in Cycles 1, 2, and 3:

      -You will have a physical exam.

      Within 7 days before receiving the first NK cell infusion in Cycles 1-3, blood (about 1
      tablespoon) will be drawn for routine tests.

      On the days of the NK cell infusions in Cycles 1-3:

      - You will have a physical exam before the infusion, which may be done at bedside.

      Right before the NK cell infusion, CSF will be withdrawn from the ommaya reservoir and used
      for routine tests. The CSF will also be used to study any tumor cells or NK cells in the CSF.

      - You will have an MRI of the brain within 72 hours before the first NK cell infusion in
      Cycle 1. An MRI of the spine will be performed at the same time if the doctor thinks it is
      needed. If these scans show the disease has gotten worse since the time of screening, it will
      serve as the baseline scan. You will still move forward with NK cell infusions if the doctor
      thinks you are stable to receive infusions.

      After you finish Cycle 3 and within 7 days after the last dose of NK cells, you will have an
      MRI of the brain to check the status of the disease. You will also have an MRI of the spine
      if the doctor thinks it is needed. MRIs can be performed earlier if the doctor thinks it is
      needed.

      You will have a brain MRI with a CINE study (checking the proper flow of CSF that surrounds
      and flows in the brain and spine) to check the flow of CSF into the spine from the brain
      before the first infusion of NK cells. This has to be performed any time after the placement
      of the catheter and the first infusion of the NK cells.

      Length of NK Cell Dosing:

      You may receive up to 3 cycles of the NK cells. You will no longer be able to receive the NK
      cells if the disease gets worse, if intolerable side effects occur, or if you are unable to
      follow study directions.

      Your participation on the study will be over after the follow-up visit.

      End-of-Dosing Visit:

      Within 30 days after completing Cycle 3:

        -  You will have a physical exam.

        -  Blood (about 1 tablespoon) will be drawn for routine tests.

        -  Within 7 days after the last infusion of NK cells, you will have an MRI of the brain and
           spine to check the status of the disease.

        -  You will have a spinal tap to withdraw a small amount of CSF from around your spinal
           cord to check for tumor cells if your doctor thinks it is appropriate.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of Autologous Natural Killer (NK) Cells</measure>
    <time_frame>4 weeks</time_frame>
    <description>Maximum Tolerated Dose (MTD) is maximum dose at which fewer than one-third of patients experience a Dose Limiting Toxicity (DLT) during cycle 1 of therapy. MTD defined as highest dose studied in which six patients have been treated and at most one patient with DLTs are observed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antitumor Activity of Autologous NK Cell Administration</measure>
    <time_frame>7 days after 3, 4 week cycles</time_frame>
    <description>Antitumor activity based on imaging and cytology. Measurable disease defined as presence of at least one lesion that can be accurately measured in two dimensions, each of which measure at least 10 mm: product of longest diameter and longest perpendicular diameter. Evaluable disease defined as at least one lesion that cannot be accurately measured in at least one dimension, or positive CSF cytology.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Brain Cancer</condition>
  <arm_group>
    <arm_group_label>Natural Killer (NK) Cell Infusions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient receives 3 cycles of Natural Killer (NK) cell infusions. Each cycle 4 weeks duration. During the first 3 weeks (Day 1-7 weekly) NK cells infused at Day 1, 3 and 5 (+/- 2 days). The 4th week will be a rest week. Follow-up visit will be 30 days from last infusion (cycle 3). Starting dose level of NK-cell number per infusion is 10^6/m^2. Infusions given through ommaya reservoir catheter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Natural Killer (NK) Cells</intervention_name>
    <description>Starting dose level of NK-cell number per infusion is 10^6/m^2. Infusions given through ommaya reservoir catheter. Participants receive the NK cells 3 times a week (at least 1 day apart) for the first 3 weeks in each 4-week cycle.</description>
    <arm_group_label>Natural Killer (NK) Cell Infusions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: &lt; 22 years at the time of recurrence or progression

          2. Diagnosis: Patients with recurrent/refractory MB, AT/RT or ependymoma involving the
             brain and/or spine at original diagnosis or relapse. They must have histological
             verification at diagnosis and/or relapse. Patient must have presented with these
             tumors in the posterior fossa (PF) or relapsed in the PF.

          3. Patient must have either measurable or evaluable tumor.

          4. Presence of or determined by neurosurgery to be a candidate for an implanted catheter
             in the ventricles to receive NK cell infusion.

          5. Life expectancy of at least 12 weeks in opinion of PI and/or designee.

          6. Lansky score of 50 or greater if &lt;/=16 years of age or a Karnofsky score of 50 or
             greater if &gt; 16 years of age (NOTE: Patients who are unable to walk because of
             paralysis, but who are in a wheelchair, will be considered ambulatory for the purpose
             of assessing the performance score).

          7. Neurologic deficits must have been relatively stable for a minimum of 1 week prior to
             study enrollment.

          8. Patients must have recovered from the acute toxic effects of all prior anticancer
             chemotherapy.

          9. Patient must be 4 weeks off any palliative radiation or craniospinal radiation

         10. Adequate bone marrow function defined by an ANC of &gt;/= 1000/ÂµL, platelet count of &gt;/=
             30,000 and hemoglobin of &gt;/= 9.0 g/dl

         11. Patients with a seizure disorder may be enrolled if well-controlled and on non- enzyme
             inducing anticonvulsants

         12. Patient or patient's legal representative, parent(s), or guardian able to provide
             written informed consent

        Exclusion Criteria:

          1. Enrolled in another treatment protocol

          2. Evidence of untreated infection

          3. Extra-cranial metastasis

          4. Chronic corticosteroid dependence (except replacement therapy)

          5. Extensive disease, disease location, and/or co-morbid condition that the PI or
             designee considers unsafe for surgical intervention of NK cell infusion

          6. Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soumen Khatua, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Soumen Khatua, MD</last_name>
    <phone>713-792-3280</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clinical Research Operations UT MD Anderson</last_name>
    <phone>713-792-7734</phone>
    <email>CR_Study_Registration@mdanderson.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MD Anderson Health Information Specialist</last_name>
      <phone>877-632-6789</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2014</study_first_submitted>
  <study_first_submitted_qc>October 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2014</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brain Cancer</keyword>
  <keyword>Brain tumor</keyword>
  <keyword>Recurrent posterior fossa tumors</keyword>
  <keyword>Central nervous system</keyword>
  <keyword>CNS</keyword>
  <keyword>Artificial antigen- presenting cells</keyword>
  <keyword>aAPC</keyword>
  <keyword>Natural killer cells</keyword>
  <keyword>NK</keyword>
  <keyword>Ommaya reservoir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Infratentorial Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

